Menin Logs Status Today

Targeting the menin

Several menin inhibitors are in development for the treatment of NPM1 m or KMT2A r AML, and revumenib has been approved by the U.S. Food and Drug Administration (FDA) for patients aged ≥1 year with KMT2A r relapsed/refractory (R/R) acute leukemia. 3 Here, we summarize the current status of menin inhibitors in development, and provide an ...

As we can see from the illustration, Menin Logs Status Today has many fascinating aspects to explore.

Rigorous assessment of MEN1 mutational status in patients across Menin inhibitors is necessary to understand the broad clinical relevance of these mutations and to determine the incidence MEN1 mutations induced by different Menin inhibitor chemotypes and in different genetic subtypes of acute leukemia.

Background: The Phase 1 AUGMENT-101 trial demonstrated that the menin inhibitor (MI) revumenib has promising activity in KMT2A -rearranged (KMT2A -r) and nucleophosmin mutant (NPM1m) acute leukemias, however 40% of patients with available DNA samples developed menin (MEN1) mutations and some acquired resistance without MEN1 mutations (Issa et al., Nature, 2023; Perner et al., Nature, 2023). As ...

Such details provide a deeper understanding and appreciation for Menin Logs Status Today.